 David Kao
Concepts (350)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 31 | 2023 | 2142 | 5.080 |
Why?
| | Stroke Volume | 16 | 2022 | 565 | 2.250 |
Why?
| | Machine Learning | 5 | 2022 | 344 | 1.950 |
Why?
| | Methadone | 5 | 2023 | 87 | 1.820 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 72 | 1.720 |
Why?
| | Adrenergic beta-Antagonists | 9 | 2019 | 366 | 1.650 |
Why?
| | Buprenorphine | 3 | 2023 | 130 | 1.640 |
Why?
| | Cardiomyopathies | 5 | 2022 | 315 | 1.590 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 324 | 1.260 |
Why?
| | Cardiomyopathy, Dilated | 8 | 2023 | 369 | 1.120 |
Why?
| | Electronic Health Records | 6 | 2022 | 821 | 1.100 |
Why?
| | Propanolamines | 3 | 2019 | 108 | 1.030 |
Why?
| | Torsades de Pointes | 4 | 2016 | 31 | 0.850 |
Why?
| | Telemedicine | 3 | 2020 | 634 | 0.840 |
Why?
| | Pulmonary Edema | 1 | 2021 | 132 | 0.820 |
Why?
| | Coffee | 1 | 2021 | 15 | 0.810 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 54 | 0.780 |
Why?
| | Stroke | 2 | 2021 | 1067 | 0.780 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 75 | 0.710 |
Why?
| | Mobile Applications | 1 | 2021 | 156 | 0.700 |
Why?
| | Decision Support Systems, Clinical | 5 | 2023 | 177 | 0.700 |
Why?
| | Device Removal | 1 | 2020 | 120 | 0.700 |
Why?
| | Prosthesis Failure | 1 | 2020 | 128 | 0.700 |
Why?
| | Long QT Syndrome | 3 | 2016 | 70 | 0.690 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 109 | 0.690 |
Why?
| | Spironolactone | 1 | 2019 | 38 | 0.690 |
Why?
| | Humans | 76 | 2023 | 121869 | 0.690 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 411 | 0.680 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 60 | 0.680 |
Why?
| | Medical Records | 2 | 2019 | 181 | 0.660 |
Why?
| | Coronary Disease | 1 | 2021 | 396 | 0.660 |
Why?
| | Mortality | 3 | 2019 | 325 | 0.650 |
Why?
| | Artificial Intelligence | 1 | 2019 | 147 | 0.650 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 40 | 0.630 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 781 | 0.620 |
Why?
| | Periodicals as Topic | 1 | 2020 | 253 | 0.610 |
Why?
| | United States | 19 | 2021 | 13209 | 0.610 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 53 | 0.600 |
Why?
| | Aged | 27 | 2022 | 20705 | 0.600 |
Why?
| | Hospital Records | 1 | 2016 | 12 | 0.590 |
Why?
| | Proteoglycans | 1 | 2017 | 106 | 0.580 |
Why?
| | Risk Assessment | 7 | 2020 | 3248 | 0.570 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 403 | 0.570 |
Why?
| | Hospitalization | 9 | 2021 | 1873 | 0.560 |
Why?
| | Tetrazoles | 1 | 2015 | 32 | 0.550 |
Why?
| | Survival | 1 | 2015 | 40 | 0.550 |
Why?
| | Disease Management | 1 | 2020 | 608 | 0.540 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 59 | 0.530 |
Why?
| | Female | 43 | 2022 | 63903 | 0.530 |
Why?
| | Retrospective Studies | 19 | 2022 | 13063 | 0.510 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1142 | 0.510 |
Why?
| | Research Design | 1 | 2020 | 1003 | 0.500 |
Why?
| | Biomedical Research | 1 | 2020 | 632 | 0.500 |
Why?
| | Loperamide | 2 | 2023 | 12 | 0.490 |
Why?
| | Registries | 2 | 2020 | 1956 | 0.480 |
Why?
| | Middle Aged | 25 | 2021 | 28961 | 0.480 |
Why?
| | United States Food and Drug Administration | 4 | 2016 | 190 | 0.470 |
Why?
| | Diet | 1 | 2021 | 1164 | 0.470 |
Why?
| | Muscle Proteins | 1 | 2015 | 226 | 0.460 |
Why?
| | Myocardium | 3 | 2017 | 1010 | 0.460 |
Why?
| | Quality Improvement | 2 | 2020 | 996 | 0.450 |
Why?
| | Male | 35 | 2022 | 60475 | 0.450 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 179 | 0.450 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2107 | 0.450 |
Why?
| | Legislation, Medical | 1 | 2012 | 11 | 0.450 |
Why?
| | Peripartum Period | 4 | 2022 | 9 | 0.450 |
Why?
| | Amiodarone | 1 | 2012 | 23 | 0.440 |
Why?
| | Pharmacogenetics | 4 | 2021 | 153 | 0.440 |
Why?
| | Patient Readmission | 1 | 2018 | 678 | 0.430 |
Why?
| | Adult | 26 | 2022 | 32683 | 0.430 |
Why?
| | Heart Arrest | 4 | 2019 | 299 | 0.410 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 139 | 0.410 |
Why?
| | Pyrazines | 2 | 2008 | 80 | 0.410 |
Why?
| | Catheter Ablation | 1 | 2015 | 338 | 0.400 |
Why?
| | Postoperative Complications | 2 | 2020 | 2322 | 0.400 |
Why?
| | Hospital Mortality | 5 | 2022 | 878 | 0.390 |
Why?
| | Triazoles | 2 | 2008 | 136 | 0.390 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 486 | 0.390 |
Why?
| | Treatment Outcome | 9 | 2021 | 9654 | 0.380 |
Why?
| | Transfusion Reaction | 1 | 2011 | 79 | 0.380 |
Why?
| | Ventricular Function, Left | 4 | 2022 | 499 | 0.370 |
Why?
| | Patient Transfer | 1 | 2012 | 165 | 0.370 |
Why?
| | Insurance, Health | 1 | 2012 | 258 | 0.370 |
Why?
| | Patient Discharge | 2 | 2021 | 843 | 0.370 |
Why?
| | Databases, Factual | 5 | 2020 | 1285 | 0.370 |
Why?
| | Anemia | 1 | 2011 | 163 | 0.350 |
Why?
| | Marketing | 1 | 2008 | 25 | 0.350 |
Why?
| | Renal Insufficiency | 1 | 2011 | 145 | 0.340 |
Why?
| | Thiazolidinediones | 1 | 2010 | 154 | 0.340 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 19 | 0.340 |
Why?
| | Risk Factors | 8 | 2020 | 9419 | 0.330 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 43 | 0.330 |
Why?
| | Simvastatin | 1 | 2008 | 67 | 0.330 |
Why?
| | Heart Ventricles | 4 | 2017 | 748 | 0.320 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 60 | 0.320 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 24 | 0.320 |
Why?
| | Drug Industry | 1 | 2008 | 108 | 0.310 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 244 | 0.310 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1190 | 0.310 |
Why?
| | Electrocardiography | 4 | 2019 | 641 | 0.310 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 901 | 0.310 |
Why?
| | Adverse Drug Reaction Reporting Systems | 3 | 2013 | 69 | 0.310 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1247 | 0.300 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 1841 | 0.300 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 169 | 0.290 |
Why?
| | Cardiovascular Diseases | 4 | 2021 | 1812 | 0.290 |
Why?
| | Precision Medicine | 5 | 2022 | 354 | 0.280 |
Why?
| | Cause of Death | 2 | 2019 | 400 | 0.270 |
Why?
| | Ventricular Remodeling | 2 | 2017 | 228 | 0.270 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2499 | 0.260 |
Why?
| | Young Adult | 9 | 2022 | 11223 | 0.260 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 651 | 0.260 |
Why?
| | Pregnancy | 6 | 2022 | 5663 | 0.260 |
Why?
| | Phenotype | 3 | 2020 | 3078 | 0.260 |
Why?
| | Pandemics | 3 | 2022 | 1316 | 0.260 |
Why?
| | Glucose | 1 | 2010 | 962 | 0.260 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 403 | 0.250 |
Why?
| | Incidence | 4 | 2021 | 2520 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1254 | 0.250 |
Why?
| | Adolescent | 10 | 2020 | 19126 | 0.240 |
Why?
| | Aged, 80 and over | 6 | 2020 | 6974 | 0.240 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.240 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 714 | 0.230 |
Why?
| | Sex Factors | 3 | 2019 | 1898 | 0.230 |
Why?
| | Biological Specimen Banks | 2 | 2022 | 79 | 0.230 |
Why?
| | Medicare | 2 | 2020 | 734 | 0.230 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 70 | 0.220 |
Why?
| | Naltrexone | 1 | 2023 | 76 | 0.220 |
Why?
| | Prognosis | 5 | 2020 | 3603 | 0.220 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1033 | 0.220 |
Why?
| | Insulin Resistance | 1 | 2010 | 1174 | 0.210 |
Why?
| | Smartphone | 1 | 2021 | 69 | 0.200 |
Why?
| | Red Meat | 1 | 2021 | 14 | 0.200 |
Why?
| | Losartan | 1 | 2020 | 13 | 0.200 |
Why?
| | Lisinopril | 1 | 2020 | 15 | 0.200 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 35 | 0.200 |
Why?
| | Referral and Consultation | 2 | 2017 | 680 | 0.200 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 21 | 0.200 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 343 | 0.200 |
Why?
| | Speech | 1 | 2021 | 85 | 0.200 |
Why?
| | Turner Syndrome | 1 | 2021 | 40 | 0.200 |
Why?
| | Angioedema | 1 | 2020 | 17 | 0.200 |
Why?
| | Time Factors | 3 | 2020 | 6889 | 0.200 |
Why?
| | Protective Factors | 1 | 2021 | 97 | 0.200 |
Why?
| | Biological Products | 1 | 2023 | 163 | 0.200 |
Why?
| | Hypertension | 2 | 2020 | 1241 | 0.200 |
Why?
| | Actigraphy | 1 | 2021 | 125 | 0.190 |
Why?
| | American Heart Association | 2 | 2019 | 312 | 0.190 |
Why?
| | Data Accuracy | 1 | 2020 | 62 | 0.190 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 66 | 0.190 |
Why?
| | Social Determinants of Health | 1 | 2022 | 137 | 0.190 |
Why?
| | California | 2 | 2012 | 386 | 0.190 |
Why?
| | Bionics | 1 | 2019 | 11 | 0.190 |
Why?
| | Milk | 1 | 2021 | 128 | 0.190 |
Why?
| | Software | 2 | 2015 | 653 | 0.190 |
Why?
| | Medical Futility | 1 | 2019 | 25 | 0.180 |
Why?
| | Editorial Policies | 1 | 2020 | 53 | 0.180 |
Why?
| | Medical Record Linkage | 1 | 2020 | 56 | 0.180 |
Why?
| | Medical Informatics | 1 | 2020 | 110 | 0.180 |
Why?
| | Drug Overdose | 1 | 2023 | 283 | 0.180 |
Why?
| | Echocardiography | 2 | 2019 | 594 | 0.180 |
Why?
| | Prescription Drugs | 1 | 2020 | 113 | 0.170 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 152 | 0.170 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 27 | 0.170 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 41 | 0.170 |
Why?
| | Drug Prescriptions | 1 | 2021 | 270 | 0.170 |
Why?
| | Tobacco Use | 1 | 2019 | 54 | 0.170 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 255 | 0.170 |
Why?
| | Cohort Studies | 3 | 2021 | 5300 | 0.170 |
Why?
| | Child Health Services | 1 | 2020 | 180 | 0.170 |
Why?
| | Computer Graphics | 2 | 2015 | 52 | 0.160 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2046 | 0.160 |
Why?
| | Genotype | 2 | 2021 | 1952 | 0.160 |
Why?
| | Florida | 1 | 2018 | 76 | 0.160 |
Why?
| | Cluster Analysis | 1 | 2019 | 512 | 0.160 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 10 | 0.160 |
Why?
| | Advisory Committees | 1 | 2019 | 220 | 0.160 |
Why?
| | Prospective Studies | 4 | 2021 | 6629 | 0.160 |
Why?
| | Length of Stay | 3 | 2021 | 1056 | 0.160 |
Why?
| | Forecasting | 1 | 2019 | 382 | 0.150 |
Why?
| | Academic Medical Centers | 1 | 2020 | 416 | 0.150 |
Why?
| | Dyslipidemias | 1 | 2019 | 164 | 0.150 |
Why?
| | Follow-Up Studies | 5 | 2020 | 4883 | 0.150 |
Why?
| | Cytochrome P-450 CYP2C19 | 3 | 2022 | 21 | 0.150 |
Why?
| | Patient Participation | 1 | 2020 | 371 | 0.150 |
Why?
| | Consensus | 1 | 2019 | 537 | 0.150 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 469 | 0.150 |
Why?
| | Pressure Ulcer | 1 | 2017 | 34 | 0.150 |
Why?
| | Nursing Assessment | 1 | 2017 | 57 | 0.150 |
Why?
| | Population Surveillance | 1 | 2020 | 439 | 0.150 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 107 | 0.150 |
Why?
| | Tilidine | 1 | 2016 | 3 | 0.150 |
Why?
| | Heart Diseases | 1 | 2020 | 372 | 0.140 |
Why?
| | Cardiology | 1 | 2019 | 335 | 0.140 |
Why?
| | Oxycodone | 1 | 2016 | 47 | 0.140 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 5 | 0.140 |
Why?
| | Genetic Markers | 1 | 2017 | 371 | 0.140 |
Why?
| | Rheumatic Fever | 1 | 2015 | 8 | 0.140 |
Why?
| | Naloxone | 1 | 2016 | 94 | 0.140 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 35 | 0.140 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 19 | 0.140 |
Why?
| | Marijuana Use | 1 | 2018 | 153 | 0.140 |
Why?
| | Sex Distribution | 1 | 2016 | 374 | 0.140 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 29 | 0.130 |
Why?
| | Databases, Genetic | 1 | 2017 | 286 | 0.130 |
Why?
| | Angiotensin II | 1 | 2015 | 109 | 0.130 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1649 | 0.130 |
Why?
| | Computational Biology | 2 | 2017 | 661 | 0.130 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 51 | 0.130 |
Why?
| | United Kingdom | 1 | 2015 | 254 | 0.130 |
Why?
| | Mothers | 1 | 2020 | 707 | 0.130 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 800 | 0.130 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 129 | 0.130 |
Why?
| | Heart Rate | 2 | 2022 | 788 | 0.120 |
Why?
| | International Classification of Diseases | 1 | 2015 | 124 | 0.120 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 530 | 0.120 |
Why?
| | Age Factors | 2 | 2019 | 3173 | 0.120 |
Why?
| | Comorbidity | 1 | 2019 | 1633 | 0.120 |
Why?
| | Chronic Disease | 2 | 2020 | 1655 | 0.120 |
Why?
| | Cholesterol | 1 | 2015 | 376 | 0.120 |
Why?
| | Gene Expression | 2 | 2017 | 1530 | 0.110 |
Why?
| | Down-Regulation | 1 | 2015 | 639 | 0.110 |
Why?
| | MicroRNAs | 2 | 2017 | 652 | 0.110 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 93 | 0.110 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 398 | 0.110 |
Why?
| | Federal Government | 1 | 2012 | 30 | 0.110 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 490 | 0.110 |
Why?
| | RNA, Messenger | 2 | 2017 | 2746 | 0.110 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 706 | 0.110 |
Why?
| | Drug Resistance | 1 | 2012 | 175 | 0.110 |
Why?
| | Area Under Curve | 1 | 2012 | 308 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1965 | 0.100 |
Why?
| | Patient Safety | 1 | 2015 | 308 | 0.100 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 113 | 0.100 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 358 | 0.100 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 205 | 0.100 |
Why?
| | Biomarkers | 1 | 2021 | 3652 | 0.100 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2377 | 0.100 |
Why?
| | Bayes Theorem | 1 | 2012 | 350 | 0.100 |
Why?
| | Survival Rate | 1 | 2015 | 1828 | 0.100 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 960 | 0.100 |
Why?
| | Double-Blind Method | 2 | 2012 | 1720 | 0.100 |
Why?
| | Managed Care Programs | 2 | 2022 | 157 | 0.090 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 198 | 0.090 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1355 | 0.090 |
Why?
| | Delivery of Health Care | 1 | 2017 | 855 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1401 | 0.090 |
Why?
| | Emergency Medical Services | 1 | 2015 | 553 | 0.090 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2876 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1574 | 0.080 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 36 | 0.080 |
Why?
| | Primary Health Care | 1 | 2019 | 1619 | 0.080 |
Why?
| | Drug Approval | 1 | 2008 | 79 | 0.080 |
Why?
| | Vasodilator Agents | 1 | 2010 | 342 | 0.080 |
Why?
| | Kidney Function Tests | 1 | 2007 | 161 | 0.080 |
Why?
| | Logistic Models | 1 | 2012 | 2037 | 0.080 |
Why?
| | Animals | 3 | 2023 | 34134 | 0.080 |
Why?
| | Colorado | 3 | 2022 | 4344 | 0.070 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 405 | 0.070 |
Why?
| | Zimbabwe | 2 | 2017 | 45 | 0.070 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 242 | 0.070 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1003 | 0.070 |
Why?
| | Depression | 2 | 2022 | 1201 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2012 | 3314 | 0.070 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 4713 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1772 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 132 | 0.060 |
Why?
| | Mandible | 1 | 2004 | 68 | 0.060 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 40 | 0.060 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 38 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 770 | 0.060 |
Why?
| | Algorithms | 3 | 2020 | 1618 | 0.060 |
Why?
| | Child | 5 | 2020 | 19282 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 41 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 81 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 125 | 0.050 |
Why?
| | Electronic Prescribing | 1 | 2021 | 5 | 0.050 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 180 | 0.050 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 219 | 0.050 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 12 | 0.050 |
Why?
| | Antidepressive Agents | 1 | 2022 | 201 | 0.050 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 25 | 0.050 |
Why?
| | Health Services Misuse | 1 | 2020 | 36 | 0.050 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 450 | 0.050 |
Why?
| | Morbidity | 1 | 2020 | 300 | 0.050 |
Why?
| | Antigens, CD | 1 | 2002 | 468 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 27 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2017 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 43 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 196 | 0.040 |
Why?
| | Bias | 1 | 2020 | 203 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2506 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2048 | 0.040 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 246 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 346 | 0.040 |
Why?
| | Inpatients | 1 | 2021 | 390 | 0.040 |
Why?
| | Focus Groups | 1 | 2019 | 382 | 0.040 |
Why?
| | Exercise Test | 1 | 2020 | 617 | 0.040 |
Why?
| | Neoplasms | 1 | 2010 | 2241 | 0.040 |
Why?
| | Pharmacovigilance | 1 | 2016 | 15 | 0.040 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 107 | 0.040 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1180 | 0.040 |
Why?
| | Frail Elderly | 1 | 2017 | 106 | 0.040 |
Why?
| | Puerperal Disorders | 1 | 2016 | 33 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 183 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 345 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 113 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 512 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 301 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 95 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 139 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1717 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1090 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 1002 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2020 | 2999 | 0.030 |
Why?
| | Mass Screening | 2 | 2013 | 1089 | 0.030 |
Why?
| | Infant | 2 | 2015 | 8440 | 0.030 |
Why?
| | Models, Genetic | 1 | 2015 | 613 | 0.030 |
Why?
| | Child, Preschool | 2 | 2015 | 9776 | 0.030 |
Why?
| | Anthracyclines | 1 | 2010 | 39 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 97 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 89 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 4810 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1012 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 227 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 876 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 218 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 108 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2564 | 0.020 |
Why?
| | Mice | 1 | 2023 | 15621 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 387 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 660 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 736 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 479 | 0.020 |
Why?
| | Dentists | 1 | 2004 | 18 | 0.020 |
Why?
| | Hospitals, University | 1 | 2005 | 183 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1289 | 0.020 |
Why?
| | Femur Neck | 1 | 2004 | 68 | 0.020 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 61 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 246 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 135 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 23 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1383 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 477 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 612 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1248 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 957 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2113 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2948 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 791 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|